Cidara Therapeutics(CDTX) - 2024 Q1 - Quarterly Results

"Our reacquisition of our CD388 program, which we have developed to date in collaboration with Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, (Janssen) as a once-per-flu season universal preventative of influenza A and B, along with the divestiture of the rezafungin program to our former partner Mundipharma, enables us to focus all of our development efforts on our Cloudbreak DFC platform," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "Our priority now is to evalu ...